Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Commentary: New York must take on Big Pharma by demanding more transparency in pricing and ensuring generics aren't delayed ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Citi views the recent volatility in shares of Royalty Pharma (RPRX) as a buying opportunity. Worries over the tariff impact to biopharma have ...

Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) ...

The benchmark indices bounced back on March 27, with the Nifty 50 climbing 105 points on the expiry day for monthly Futures & ...

UTC+8Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8MFirst-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical ...

Hero MotoCorp, Bajaj Finserv, IndusInd Bank, HDFC Life, NTPC were among major gainers on the Nifty, while losers were Tata ...